Apr 20, 2022
Why angel-scale biotech is so promising: Learn More
Qiuyan Xu, PhD is a statistician, an entrepreneur and a colleague at Walnut. We talked about the startups she has invested in, her immigrant journey and the work she does at Gravitate AI (https://www.gravitate.ai)
Sponsors: Purdue University entrepreneurship & Peter Fasse, patent attorney at Fish & Richardson
Highlights:
- Sal Daher Introduces Qiuyan Xu, PhD, Statistician, Entrepreneur and Angel Investor
- Qiuyan Xu Talks About Her Investment in AOA Diagnostics
- Qiuyan Xu Talks About Her Investment in Octagon Therapeutics
- What Sal Daher Looks for in an Academic Founder
- Qiuyan Xu Wonders About the Long Holds in Life Science Investments
- “It's an important thing to remember now that the early-stage, angel-scale life science investing is really, really just beginning to take off.”
- “There are some angels who have done very successfully, with just a handful of companies.”
- “Weeding out the obvious losers. I think it makes a lot of sense.”
- We Still Know Surprisingly Little in the Life Sciences
- Qiuyan Xu Came to the US in 2003 to Study Statistics at UC Davis
- “...I got my PhD in 2008, in statistics, in the middle of a recession.”
- What Drove Qiuyan Xu to Become an Entrepreneur
- Qiuyan Xu’s Company Is Gravitate AI (https://www.gravitate.ai/)
- Gravitate AI Helps with Data Cleaning & Automation as Well as Customizing Open-Source AI Solutions
- How Qiuyan Xu Became an Angel Investor
- Contagious Enthusiasm
- Qiuyan Xu’s Advice to Angel Investors
- “You're urging angels to step right in, but at the same time, exercise control and have a budget.”
- Advice to Founders
Topics: robotics / AI, discovering entrepreneurship, angel investing strategies